Brokerages Set Denali Therapeutics Inc. (NASDAQ:DNLI) PT at $32.27

Denali Therapeutics Inc. (NASDAQ:DNLI) has earned an average rating of “Buy” from the fourteen research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, eleven have given a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $32.2727.

Several research analysts have recently weighed in on DNLI shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, January 21st. UBS Group started coverage on shares of Denali Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating on the stock. Wedbush cut their target price on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Thursday, December 11th. Morgan Stanley reaffirmed an “overweight” rating and issued a $40.00 target price on shares of Denali Therapeutics in a research report on Thursday, January 8th. Finally, Stifel Nicolaus set a $37.00 price target on Denali Therapeutics in a report on Monday, November 17th.

Denali Therapeutics Trading Down 0.2%

Shares of NASDAQ DNLI opened at $20.19 on Friday. The company has a quick ratio of 9.79, a current ratio of 9.79 and a debt-to-equity ratio of 0.01. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $23.77. The company has a market cap of $2.96 billion, a price-to-earnings ratio of -6.94 and a beta of 1.02. The business has a fifty day simple moving average of $18.65 and a 200-day simple moving average of $16.82.

Insider Transactions at Denali Therapeutics

In other Denali Therapeutics news, insider Alexander O. Schuth sold 17,218 shares of the company’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $284,097.00. Following the transaction, the insider owned 282,828 shares in the company, valued at approximately $4,666,662. This represents a 5.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ryan J. Watts sold 35,198 shares of the stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $580,767.00. Following the completion of the sale, the chief executive officer owned 296,833 shares of the company’s stock, valued at approximately $4,897,744.50. The trade was a 10.60% decrease in their position. The SEC filing for this sale provides additional information. 12.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Denali Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. AlphaQuest LLC raised its stake in shares of Denali Therapeutics by 224.1% during the 3rd quarter. AlphaQuest LLC now owns 74,422 shares of the company’s stock worth $1,081,000 after purchasing an additional 51,458 shares in the last quarter. Aberdeen Group plc grew its stake in shares of Denali Therapeutics by 23.4% in the 3rd quarter. Aberdeen Group plc now owns 1,113,586 shares of the company’s stock valued at $16,169,000 after buying an additional 210,835 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Denali Therapeutics by 18.5% in the third quarter. Principal Financial Group Inc. now owns 1,271,190 shares of the company’s stock worth $18,458,000 after buying an additional 198,207 shares during the last quarter. Schroder Investment Management Group raised its position in Denali Therapeutics by 32.5% during the second quarter. Schroder Investment Management Group now owns 386,539 shares of the company’s stock valued at $5,408,000 after acquiring an additional 94,744 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC raised its position in Denali Therapeutics by 51.9% during the third quarter. Campbell & CO Investment Adviser LLC now owns 216,774 shares of the company’s stock valued at $3,148,000 after acquiring an additional 74,066 shares in the last quarter. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.